ProductsBack/InVivoMAb anti-Dengue virus type 4 E protein DIII

InVivoMAb anti-Dengue virus type 4 E protein DIII

Name: InVivoMAb anti-Dengue virus type 4 E protein DIII
SKU: BE0437_B56
Availability: BackOrder

BE0437

ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking

Product group Antibodies

ReactivityVirus

Overview

Chen RE, Smith BK, Errico JM, et al. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021,29(11):1634-1648.e5. doi: 10.1016/j.chom.2021.09.006
Read this paper
Khetarpal N, Shukla R, Rajpoot RK, et al. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. Am J Trop Med Hyg. 2017,96(1):126-134. doi: 10.4269/ajtmh.16-0503
Read this paper
Gallichotte EN, Widman DG, Yount BL, et al. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio. 2015,6(5):e01461-15. doi: 10.1128/mBio.01461-15
Read this paper
Sukupolvi-Petty S, Brien JD, Austin SK, et al. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol. 2013,87(16):8826-42. doi: 10.1128/JVI.01314-13
Read this paper